Abstracts tagged "Biomarkers"

Abstract Number: L11 • ACR Convergence 2024
Rheumatology Diagnostics Utilizing Artificial Intelligence (ANA Reader©) for ANA Pattern Identification and Titer Quantification
May Choi¹, Farbod Moghaddam¹, Mohammad Sajadi¹, Ann E. Clarke¹, Sasha Bernatsky², Karen Costenbader³, Irene Chen⁴, Murray Urowitz⁵, John Hanly⁶, Caroline Gordon⁷, Sang-Cheol Bae⁸, Juanita Romero-Diaz⁹, Jorge Sanchez-Guerrero¹⁰, Daniel Wallace¹¹, David Isenberg¹², Anisur Rahman¹³, Joan Merrill¹⁴, Paul Fortin¹⁵, Dafna Gladman¹⁶, Ian Bruce¹⁷, Michelle Petri¹⁸, Ellen Ginzler¹⁹, Mary Anne Dooley²⁰, Rosalind Ramsey-Goldman²¹, Susan Manzi²², Andreas Jönsen²³, Graciela Alarcón²⁴, Ronald Van Vollenhoven²⁵, Cynthia Aranow²⁶, Meggan Mackay²⁶, Guillermo Ruiz-Irastorza²⁷, S. Sam Lim²⁸, Murat Inanç²⁹, Kenneth Kalunian³⁰, Soren Jacobsen³¹, Christine Peschken³², Diane Kamen³³, Anca Askanase³⁴, Marvin Fritzler³⁵ and Mina Aminghafari¹, ¹University of Calgary, Calgary, AB, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Brigham and Women's Hospital/Harvard Medical School, Boston, MA, ⁴UC Berkeley and UCSF, Berkeley, CA, ⁵Self employed, Toronto, ON, Canada, ⁶Dalhousie University, Halifax, NS, Canada, ⁷University of Birmingham, Birmingham, United Kingdom, ⁸Hanyang University Medical Center, Seoul, South Korea, ⁹The National Institute of Medical Sciences and Nutrition, Mexico City, Mexico, ¹⁰Krembil Research Institute, Toronto, ON, Canada, ¹¹Cedars Sinai Medical Center, Studio City, CA, ¹²Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine, University College London, London, United Kingdom, ¹³University College London, London, United Kingdom, ¹⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Centre ARThrite - CHU de Québec - UniversitéLaval, Quebec, QC, Canada, ¹⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁷Queen's University Belfast, Belfast, United Kingdom, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹SUNY Downstate Health Sciences University, New York, NY, ²⁰UNC physician network, Chapel Hill, NC, ²¹Northwestern University, Chicago, IL, ²²Allegheny Health Network, Pittsburgh, PA, ²³Lund University, Lund, Sweden, ²⁴The University of Alabama at Birmingham, Oakland, CA, ²⁵Amsterdam UMC, Amsterdam, Netherlands, ²⁶Feinstein Institutes for Medical Research, New York, NY, ²⁷Biobizkaia Health Research Institute, Bilbao, Spain, ²⁸Emory University, Atlanta, GA, ²⁹Istanbul University, Istanbul, Turkey, ³⁰UC San Diego, La Jolla, CA, ³¹Rigshospitalet, Copenhagen, Denmark, ³²University of Manitoba, Winnipeg, MB, Canada, ³³Medical University of South Carolina, Johns Island, SC, ³⁴Columbia University Medical Center, New York, NY, ³⁵Mitogen Diagnostics Corp, Calgary, AB, Canada
Background/Purpose: Antinuclear antibody (ANA) immunofluorescence (IFA) patterns and titers are a key part of rheumatology diagnostics, however, there is considerable intra- and inter-laboratory variability with…
Abstract Number: 0229 • ACR Convergence 2024
An Early Inflammatory Cardiac Phenotype and Association with Future Coronary Plaque Burden in Rheumatoid Arthritis
Brittany Weber¹, Feng Liu², Mary Jeffway², Dana Weisenfeld², Gregory McDermott³, Elena Massarotti², Jonathan Coblyn², Michael Weinblatt⁴, Marcelo Di Carli², Damini Dey⁵ and Katherine Liao², ¹Brigham and Women's Hospital, DEDHAM, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Brookline, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁵Cedars-Sinai Medical Center, Los Angeles
Background/Purpose: Patients with RA are at increased risk of cardiovascular disease (CVD) compared to the general population. In a prior study of RA patients with…
Abstract Number: 0464 • ACR Convergence 2024
Increases in Paraoxonase-1 Activity over Time Associates with Reduced Risk of Incident Inflammatory Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population
Amir Razmjou¹, Rong Guo², David Elashoff³, Kevin Deane⁴, Jill Norris⁵, Marie Feser⁶, Jennifer Wang¹, Ani Shahbazian² and christina Charles-Schoeman⁷, ¹UCLA, Los Angeles, CA, ²UCLA, Los Angeles, ³UCLA Department of Medicine Statistics Core, Los Angeles, ⁴University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁵Colorado School of Public Health, Denver, CO, ⁶Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁷UCLA Medical Center, Santa Monica, CA
Background/Purpose: Rheumatoid arthritis (RA) has a well described pre-clinical state, with a continuum of genetic and environmental risk factors leading to the development of systemic…
Abstract Number: 0605 • ACR Convergence 2024
Guselkumab Binding to CD64+ IL-23–Producing Myeloid Cells Enhances Potency for Neutralizing IL-23 Signaling
Dennis McGonagle¹, Raja Atreya², Maria Abreu³, James Krueger⁴, Kilian Eyerich⁵, Robert Bissonnette⁶, Carrie Greving⁷, He Li⁸, Tom C. Freeman⁹, Amy Hart⁸, Brice Keyes⁷, Brian Stoveken⁸, John Hartman⁸, Kristin Leppard⁸, Jenna Parrett¹⁰, Joshua Wertheimer⁸, Indra Sarabia⁷, Janise Deming⁷, Kristen Kohler⁷, Christopher Ritchlin¹¹, Iain McInnes¹², Matthieu Allez¹³, Anne Fourie⁷ and Kacey Sachen⁷, ¹National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK, Leeds, England, United Kingdom, ²Department of Medicine I, Gastroenterology, Endocrinology and Pneumology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, ³Leonard M. Miller School of Medicine, University of Miami, Miami, FL, ⁴The Rockefeller University, Laboratory for Investigative Dermatology, New York, NY, ⁵Karolinska Institute, Department of Medicine – Division of Dermatology and Venereology, Stockholm, Sweden; Medical Center, University of Freiburg, Freiburg, Germany, ⁶Innovaderm Research Inc., Montréal, QC, Canada, ⁷Janssen Research & Development, LLC, Immunology, San Diego, CA, ⁸Janssen Research & Development, LLC, Therapeutics Discovery, Spring House, PA, ⁹Janssen Research & Development, LLC, Spring House, PA, USA, Spring House, PA, ¹⁰Janssen Scientific Affairs, LLC, Horsham, PA, ¹¹Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ¹²University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ¹³Hôpital Saint-Louis, Université Paris Cité, Paris, France
Background/Purpose: IL-23 is implicated in the pathogenesis of psoriasis (PsO), and myeloid cells that express FcγRI (CD64) have been identified as a primary source of…
Abstract Number: 0710 • ACR Convergence 2024
High S100A4 Levels Associate with Inflammation and Vasculopathy in Systemic Sclerosis
Adela-Cristina Sarbu¹, Håvard Fretheim², Ladislav Šenolt³, Henriette Didriksen⁴, Cosimo Bruni⁵, Marco Sprecher⁶, Thor Ueland⁷, Jonas Hallén⁸, Rizwan Hussain⁹, Jörg Klingelhöfer¹⁰, Michal Tomcik¹¹, Yannick Allanore¹², Oliver Distler¹³ and Anna-Maria Hoffmann-Vold², ¹University Hospital Zurich, University of Zurich, Department of Rheumatology, Bern, Switzerland, ²Oslo University Hospital, Oslo, Norway, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Oslo University Hospital, Moss, Norway, ⁵University of Zurich, Zurich, Switzerland, ⁶Universitätsspital Zürich (University Hospital Zurich), Zürich, Switzerland, ⁷Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, ⁸Arxx Therapeutics, Oslo, Norway, Oslo, Norway, ⁹Agiana Therapeutics, Oslo, Norway, Oslo, Norway, ¹⁰Calluna Pharma, Oslo, Norway, Oslo, Norway, ¹¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ¹²Université Paris Cité, Paris, France, ¹³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: S100A4, a member of the S100 protein family, is implicated in various cellular processes. In systemic sclerosis (SSc), S100A4 is believed to contribute to…
Abstract Number: 0852 • ACR Convergence 2024
3-dimensional Shape Changes of the Knee over 4 Years Are Linear and Progressive but Much More Rapid in Osteoarthritic Joints: Data from the Osteoarthritis Initiative
Alan Brett¹, Philip G Conaghan² and Michael Bowes³, ¹Imorphics, Austin, TX, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³Imorphics, Manchester, United Kingdom
Background/Purpose: The specific bony changes of osteophyte growth and “bone attrition” (broadening and flattening of the femoral condyles) associated with OA have been recognized in…
Abstract Number: 1094 • ACR Convergence 2024
Longitudinal Analysis of Serum Urate in Prediabetic Phase
Javier Marrugo¹, Leah Santacroce¹, Misti Paudel², Sho Fukui³, Sara Tedeschi¹ and Daniel Solomon⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ³Brigham and Women's Hospital, Brookline, MA, ⁴Brigham and Women's Hospital, Newton, MA
Background/Purpose: More than 460 million people worldwide are currently living with prediabetes, a condition that not only predisposes individuals to diabetes (DM) but also to…
Abstract Number: 1326 • ACR Convergence 2024
Which Biomarkers Indicate Imminent Progression to Inflammatory Arthritis in High Risk CCP Positive Persons?
Laurence Duquenne¹, Didem Sahin Eroglu², Jianhua Wu³, Kate Harnden¹, Andrea Di Matteo⁴, Lucy Elizabeth Thornton⁵, Rahaymin Chowdhury⁵, Leticia Garcia-Montoya¹, Kulveer Mankia⁶ and Paul Emery⁶, ¹1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, United Kingdom, ²1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Ankara, Turkey, ³1. University of Leeds, Leeds Institute for Data Analytics, Leeds, United Kingdom 2.Wolfson Institute of Population Health/Queen Mary University of London, UK, Leeds, ⁴1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Jesi, Italy, ⁵1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, ⁶University of Leeds, Leeds, United Kingdom
Background/Purpose: A risk stratification model proposed a simple score using 4 biomarkers to identify those at high risk of developing inflammatory arthritis (IA) in primary…
Abstract Number: 1571 • ACR Convergence 2024
Growth Differentiation Factor 15 Is a Serum Biomarker and Pathogenic Factor of Progressive Fibrosis in Systemic Sclerosis
Vishal Kakkar¹, Sunhwa Kim², Yingtao Bi³, Christopher Wasson¹, Stefano Di Donato⁴, Rebecca Ross⁵, Marco Di Battista⁶, Enrico De Lorenzis⁷, Thierry Sornasse² and Francesco Del Galdo¹, ¹University of Leeds, Leeds, United Kingdom, ²AbbVie, South San Francisco, CA, ³Abbvie, Worcester, MA, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ⁵Medicine and Health, University of Leeds, Leeds, United Kingdom, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Pisa, United Kingdom, ⁷Catholic University of the Sacred Heart, Roma, Rome, Italy
Background/Purpose: In systemic sclerosis (SSc), interstitial lung disease (ILD) remains the leading cause of mortality. A decline in forced vital capacity (FVC) is considered a…
Abstract Number: 1811 • ACR Convergence 2024
The Immune Map of Lupus Nephritis: A Spatially Resolved Kidney Proteomic Approach
Chen-Yu Lee¹, Matthew Caleb Marlin², Xiaoping Yang¹, Alessandra Ida Celia³, Vasileios Morkotinis⁴, Richard Furie⁵, Jill Buyon⁶, Chaim Putterman⁷, Jennifer Barnas⁸, Kenneth Kalunian⁹, Peter Izmirly¹⁰, Betty Diamond¹¹, Anne Davidson¹², Diane Kamen¹³, Jeff Hodgin¹⁴, the Accelerating Medicines Partnership RA/SLE¹⁵, Judith James², Michelle Petri¹⁶, Joel Guthridge², Avi Rosenberg¹ and Andrea Fava¹, ¹Johns Hopkins UNiversity, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Sapienza University of Rome, Rome, Italy, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Northwell Health, Manhasset, NY, ⁶NYU Grossman School of Medicine, New York, NY, ⁷Albert Einstein College of Medicine, Safed, Israel, ⁸University of Rochester, Rochester, NY, ⁹University of California San Diego, La Jolla, CA, ¹⁰New York University Grossman School of Medicine, New York, NY, ¹¹The Feinstein Institutes for Medical Research, Manhasset, NY, ¹²Feinstein Institutes for Medical Research, Manhasset, NY, ¹³Medical University of South Carolina, Charleston, SC, ¹⁴University of Michigan, Michigan, ¹⁵multiple, multiple, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Treatment response rates in lupus nephritis (LN) remain suboptimal, highlighting the need for a better understanding of LN pathogenesis to enhance treatment strategies. Single-cell…
Abstract Number: 2104 • ACR Convergence 2024
The Relationship of Soluble Biomarkers to OA Pain: A Systematic Literature Review
Sylvain Mathieu¹, Liisa Kuhi², Philip G Conaghan³, Niels Eijkelkamp⁴, Yves Henrotin⁵, Eva Kosek⁶, Hans-George Schaible⁷, Ali Mobasheri⁸, Kalle Kisand⁹ and Jérémie Sellam¹⁰, and GO-PAIN working group, ¹CHU Gabriel Montpied, Clermont-Ferrand, France, ²East Tallinn Central Hospital, Tallinn, Estonia, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁴University Medical Center, Umtrecht, Netherlands, ⁵MusculoSkeletal Innovative research Lab (mSKIL), Liege, Belgium, ⁶Karolinska Institute, Stockholm, Sweden, ⁷Institute of Physiology, Jena, Germany, ⁸Research Unit of Medical Imaging, Physics and Technology, Ouli, Finland, ⁹University of Tartu, Tartu, Estonia, ¹⁰Saint-Antoine Hospital - AP-HP, Paris, Ile-de-France, France
Background/Purpose: Chronic joint pain is a major factor driving poor quality of life in people with osteoarthritis (OA). A better understanding of the complex mechanisms…
Abstract Number: 2366 • ACR Convergence 2024
Improvement in Pain-Associated Biomarkers with Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with PsA in a Double-Blind Phase 2 Study (IM011-084)
Philip Mease¹, Christopher Ritchlin², Lu Gao³, Peter Schafer⁴, Miroslawa Nowak³, Ian M. Catlett³ and Jinqi Liu³, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ³Bristol Myers Squibb, Princeton, NJ, ⁴Bristol Myers Squibb, BELLE MEAD, NJ
Background/Purpose: Pain is a core domain of PsA, and reduction of pain is a primary treatment concern for patients with PsA. Pain has been reported…
Abstract Number: 2572 • ACR Convergence 2024
Biomarker-guided Treatment-and-stop-strategy for Recombinant IL-1Receptor Antagonist (Anakinra) in Patients with Systemic Juvenile Idiopathic Arthritis
Remco Erkens¹, Gerda Den Engelsman¹, Sytze De Roock¹, Dörte Hamann¹, Dieneke Schonenberg-Meinema², Merlijn van den Berg², Mariken Gruppen³, Wineke Armbrust⁴, Elizabeth Legger⁵, Sylvia Kamphuis⁶, Marleen Verkaaik⁷, Ellen Schatorjé⁸, Esther Hoppenreijs⁸, Thomas Vogl⁹, Johannes Roth⁹, Petra Hissink Muller¹⁰, Joost Swart¹, Marc Jansen¹, Jorg van Loosdregt¹¹ and Sebastiaan Vastert¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²Amsterdam University Medical Center, Amsterdam, Netherlands, ³Amsterdam UMC, Amsterdam, Netherlands, ⁴University Medical Hospital Groningen, Groningen, Netherlands, ⁵University Medical Center Groningen, Groningen, Netherlands, ⁶Erasmus University Medical Center, Rotterdam, Netherlands, ⁷Erasmus Medical Center Rotterdam, Rotterdam, Netherlands, ⁸University Medical Center Radboud, Nijmegen, Nijmegen, Netherlands, ⁹University of Münster, Münster, Germany, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹University Medical Center Utrecht, La Jolla, CA
Background/Purpose: Early initiation of treatment with the recombinant Interleukin 1 receptor antagonist (IL-1Ra), anakinra, in Still’s disease (SD), specifically systemic Juvenile Idiopathic Arthritis, patients is…
Abstract Number: 0270 • ACR Convergence 2024
Longitudinal Patterns of C-Reactive Protein Values in Calcium Pyrophosphate Deposition (CPPD) Disease
Muneet Gill, Hongshu Guan, Jamie Collins and Sara Tedeschi, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease is a crystalline arthritis affecting older adults. Systemic inflammation occurs during flares of acute calcium pyrophosphate (CPP) crystal arthritis…
Abstract Number: 0468 • ACR Convergence 2024
Plasma Calprotectin Assessed in Multiple Biological Treatment Strategies for Early Rheumatoid Arthritis over 48 Weeks
David Stevens¹, Lene Sundbakk², Amirhossein Kazemi², Marte Heiberg³, Tuulikki Sokka-Isler⁴, Bjorn Gudbjornsson⁵, Kristina Lend⁶, Anna Rudin⁷, Michael Nurmohamed⁸, Jon Lampa⁹, Merete Hetland¹⁰, Mikkel Ostergaard¹¹, Ronald Van Vollenhoven¹², Tillmann Uhlig², Espen Haavardsholm² and Hilde Hammer³, ¹St. Olavs hospital, Trondheim, Norway, ²Diakonhjemmet Hospital, Oslo, Norway, ³Diakonhjemmet Hospital, Oslo, Oslo, Norway, ⁴University of Eastern Finland, Faculty of Health Sciences, Jyvaskyla, Finland, ⁵Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ⁶Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, ⁷Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, ⁸Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁹Karolinska University Hospital, Hässelby, Sweden, ¹⁰Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ¹¹Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ¹²Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Plasma calprotectin is a sensitive biomarker of inflammation in patients with rheumatoid arthritis (RA) and reflects activation of granulocytes and macrophages. Calprotectin has not…

1
2
3
…
96
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].